Evidence map›Paper›PMID 32582358›Full record

ArticleResearch in pharmaceutical sciences2020

Targeting of cholera toxin A (

Nafiseh Hosseini, Hossein Khanahmad, Bahram Nasr Esfahani, Mojgan Bandehpour, Laleh Shariati, Nushin Zahedi, Bahram Kazemi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nafiseh HosseiniDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran.
Hossein KhanahmadDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Bahram Nasr EsfahaniDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Mojgan BandehpourCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran.
Laleh ShariatiBiosensor Research Center, Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Nushin ZahediDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Bahram KazemiDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran.
Isfahan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe study was launched to use zinc finger nuclease (ZFN) technology to disrupt the cholera toxin gene ( EXPERIMENTAL APPROACH: An engineered ZFN was designed to target the catalytic site of the FINDINGS/

resultsNo expression was observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting in transformed CONCLUSIONS AND IMPLICATIONS: ZFN might have off target on bacterial genome causing lethal double-strand DNA break due to lack of non-homologous end joining (NHEJ) mechanism. It is recommended to develop ZFNs against bacterial genes, engineered packaging host with NHEJ repair system is essential.

Indexed as

ctxA GeneGene editing toolsVibrio choleraeZinc finger nuclease

Identifiers

PMID32582358
PMCPMC7306252
OpenAlexW3021565076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.